window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : February 3, 2026

  • News
  • About Us
Contact Us

Market Access & Commercialization

  • Infectious Diseases,Market Access & Commercialization,Medical devices

    Biocomposites launches SYNICEM spacers in Canada for joint revision surgery

    Biocomposites has launched its SYNICEM antibiotic-loaded preformed spacers in Canada, [...]

    January 30, 2026
  • Drug Delivery & Formulation,Healthcare leadership,Market Access & Commercialization,Medical devices,Movers & Shakers

    ViCentra appoints Reman McDonagh as vice president, global marketing to support Kaleido scale-up

    ViCentra has appointed Reman McDonagh as vice president, global marketing [...]

    January 29, 2026
  • Cardiovascular diseases,Drug approval,Market Access & Commercialization,Pharmaceuticals and therapeutics

    Milestone launches CARDAMYST nasal spray for PSVT in the United States

    Milestone Pharmaceuticals has announced the commercial availability of CARDAMYST (etripamil) [...]

    January 26, 2026
  • Digital Health,Market Access & Commercialization,Medical devices,Research & Development,Technology and platforms

    Profusa launches Lumee tissue oxygen research offering to generate first commercial revenue

    Profusa has launched a research-use-only version of its Lumee tissue [...]

    January 19, 2026
  • CDMOs & Manufacturing,Clinical Development,Manufacturing,Market Access & Commercialization,Oncology

    Symbiosis manufactures first commercial-scale batch at new Stirling facility

    Symbiosis Pharmaceutical Services has completed its first commercial-scale manufacturing run [...]

    January 5, 2026
  • Dermatology,Market Access & Commercialization,Medical devices,Partnerships & Funding

    Hyphens Pharma out-licenses Cerapro MED cream for six European markets

    Hyphens Pharma International Limited (Hyphens Pharma), a Singapore-based specialty pharmaceutical [...]

    January 5, 2026
  • Drug Development,Market Access & Commercialization,Opthalmology,Pharmaceuticals and therapeutics,Rare Diseases

    Age-related macular degeneration market across 7MM forecast to reach $20.5 billion by 2034

    The age-related macular degeneration market across the seven major markets [...]

    December 29, 2025
  • Biotech,Market Access & Commercialization,Mergers & Acquisitions,Pharmaceuticals and therapeutics

    Biopharma enters 2026 with cautious optimism as dealmaking and pipelines regain focus

    The biopharmaceutical industry is heading into 2026 with renewed but [...]

    December 29, 2025
  • CDMOs & Manufacturing,Clinical Development,Digital Health,Market Access & Commercialization,Patient Centricity

    Seven lords a-leaping: Gifthealth CEO on why DTP must blend high tech with high touch in 2026

    For Seven lords a-leaping, Discover Pharma turns to Chip Parkinson, [...]

    December 18, 2025
  • Facilities and infrastructure,Logistics and distribution,Market Access & Commercialization,Packaging

    Tjoapack expands US site to bolster packaging capacity and cold chain capabilities

    Tjoapack is expanding its US operations with a major build [...]

    December 10, 2025
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Skyhawk Therapeutics reports positive nine-month interim results for SKY-0515 in Huntington’s disease
    Categories: Central Nervous System, Clinical Trials, Drug Development, Rare Diseases, Research & Development
  • iOrganBio appoints Karol Jarzabek as chief operating officer
    Categories: Biologics & Biosimilars, Cell & Gene Therapy, Healthcare leadership, Manufacturing, Movers & Shakers, Pharmaceuticals and therapeutics
  • iXCells Biotechnologies partners with Rosebud Biosciences to advance organoid models for rare diseases
    Categories: Biologics & Biosimilars, Cell & Gene Therapy, Clinical Development, Drug Development, Rare Diseases, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top